United Therapeutics (NASDAQ:UTHR) CEO Sells $5,376,810.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $565.98, for a total value of $5,376,810.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,929,547.74. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

United Therapeutics Trading Up 0.5%

NASDAQ UTHR opened at $568.43 on Friday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The stock has a 50-day moving average of $563.25 and a 200-day moving average of $511.57. The firm has a market cap of $24.13 billion, a PE ratio of 20.98, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the firm posted $6.63 EPS. The company’s revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. AE Wealth Management LLC raised its position in shares of United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC raised its position in shares of United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Optimize Financial Inc bought a new position in shares of United Therapeutics in the 3rd quarter worth approximately $444,000. Tobam raised its position in shares of United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after acquiring an additional 4,953 shares in the last quarter. Finally, Perpetual Ltd bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $1,059,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent analyst reports. HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. UBS Group upped their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Bank of America upped their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Finally, Cantor Fitzgerald upped their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.